| abstract |
The present invention is concerned with compounds of formula 1 ##STR1## wherein R 0 is alkyl, alkoxy or alkylthio having 1-4 carbon atoms, hydroxy, halogen, n Z, together with the carbon atom and the nitrogen atom and the intermediate carbon atom, constitutes a heterocyclic group which consists of 5-8 ring atoms, in which, besides the already present nitrogen atom, a second hetero atom from the group N, O, or S may be present, which ring may be substituted with 1-4 methyl group, or which ring may be annelated with a phenyl group optionally substituted with fluorine, or a methyl or methoxy group; n A is a group of formula 2 or 3 ##STR2## wherein one of the groups R 3 , R 4 and R 5 is hydrogen, alkyl having 1-6 carbon atoms, cycloalkyl having 3-7 carbon atoms, alkenyl having 2-6 carbon atoms or phenyl alkyl having 1-3 carbon atoms in the alkyl group, and the two other groups independently of each other are hydrogen or alkyl having 1-4 carbon atoms, or wherein A is a polycyclic ring system in which one carbon atom is replaced by a tertiary nitrogen atom, for example, a ring system of formula 4, 5 or 6, ##STR3## wherein p is an integer having the value 1 or 2, q is an integer having the value 2, 3 or 4, r is an integer having the value 1, 2 or 3, and R 6 is alkyl having 1-4 carbon atoms, cycloalkyl having 3-6 carbon atoms, cyclopropylmethyl, allyl, propargyl or benzyl, and n B is an oxygen atom or a group ═N--R, wherein R is hydrogen, alkyl having 1-6 carbon atoms or benzyl, or wherein n B-A represents a group of formula 7 ##STR4## wherein R 3 and R 5 having the meanings defined above, and the pharmaceutically acceptable acid addition salts thereof, which are pharmaceutically active as 5-HT receptor antagonists, and pharmaceutical products containing these compounds. |